Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
TLRY vs CRON
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
TLRY vs CRON — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $671M | $1000M |
| Revenue (TTM) | $1.17B | $193M |
| Net Income (TTM) | $-2.95B | $-9M |
| Gross Margin | 28.0% | 32.5% |
| Operating Margin | -266.0% | -1.5% |
| Forward P/E | — | 34.9x |
| Total Debt | $451M | $2M |
| Cash & Equiv. | $304M | $792M |
TLRY vs CRON — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | 100 | 58.5 | -41.5% |
| Cronos Group Inc. (CRON) | 100 | 40.1 | -59.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TLRY vs CRON
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TLRY is the clearest fit if your priority is momentum.
- +12.7% vs CRON's +41.6%
CRON carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.98
- Rev growth 64.4%, EPS growth -100.0%, 3Y rev CAGR 30.6%
- 14.9% 10Y total return vs TLRY's -74.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 64.4% revenue growth vs TLRY's 4.8% | |
| Quality / Margins | -4.9% margin vs TLRY's -252.6% | |
| Stability / Safety | Beta 0.98 vs TLRY's 2.03, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +12.7% vs CRON's +41.6% | |
| Efficiency (ROA) | -0.8% ROA vs TLRY's -100.6%, ROIC -0.8% vs -66.2% |
TLRY vs CRON — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TLRY vs CRON — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CRON leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TLRY is the larger business by revenue, generating $1.2B annually — 6.0x CRON's $193M. Profitability is closely matched — net margins range from -4.9% (CRON) to -2.5% (TLRY).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.2B | $193M |
| EBITDAEarnings before interest/tax | -$3.0B | -$810,000 |
| Net IncomeAfter-tax profit | -$2.9B | -$9M |
| Free Cash FlowCash after capex | -$94M | -$163,766 |
| Gross MarginGross profit ÷ Revenue | +28.0% | +32.5% |
| Operating MarginEBIT ÷ Revenue | -2.7% | -1.5% |
| Net MarginNet income ÷ Revenue | -2.5% | -4.9% |
| FCF MarginFCF ÷ Revenue | -8.1% | -0.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.0% | +2.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +70.7% | -100.0% |
Valuation Metrics
TLRY leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $671M | $1000M |
| Enterprise ValueMkt cap + debt − cash | $818M | $209M |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | — |
| Forward P/EPrice ÷ next-FY EPS est. | — | 34.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.60x | 5.17x |
| Price / BookPrice ÷ Book value/share | 0.25x | 0.91x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CRON leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
CRON delivers a -0.9% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-137 for TLRY. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to TLRY's 0.22x. On the Piotroski fundamental quality scale (0–9), CRON scores 6/9 vs TLRY's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -136.5% | -0.9% |
| ROA (TTM)Return on assets | -100.6% | -0.8% |
| ROICReturn on invested capital | -66.2% | -0.8% |
| ROCEReturn on capital employed | -78.1% | -0.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.22x | 0.00x |
| Net DebtTotal debt minus cash | $147M | -$790M |
| Cash & Equiv.Liquid assets | $304M | $792M |
| Total DebtShort + long-term debt | $451M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -89.43x | — |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLRY five years ago would be worth $4,071 today (with dividends reinvested), compared to $3,438 for CRON. Over the past 12 months, TLRY leads with a +1268.2% total return vs CRON's +41.6%. The 3-year compound annual growth rate (CAGR) favors TLRY at 27.5% vs CRON's 9.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -40.7% | -3.0% |
| 1-Year ReturnPast 12 months | +1268.2% | +41.6% |
| 3-Year ReturnCumulative with dividends | +107.2% | +31.7% |
| 5-Year ReturnCumulative with dividends | -59.3% | -65.6% |
| 10-Year ReturnCumulative with dividends | -74.3% | +1487.9% |
| CAGR (3Y)Annualised 3-year return | +27.5% | +9.6% |
Risk & Volatility
CRON leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CRON is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRON currently trades 76.4% from its 52-week high vs TLRY's 36.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.03x | 0.98x |
| 52-Week HighHighest price in past year | $15.70 | $3.43 |
| 52-Week LowLowest price in past year | $0.35 | $1.83 |
| % of 52W HighCurrent price vs 52-week peak | +36.7% | +76.4% |
| RSI (14)Momentum oscillator 0–100 | 36.7 | 50.0 |
| Avg Volume (50D)Average daily shares traded | 4.6M | 1.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TLRY as "Hold" and CRON as "Hold". Consensus price targets imply 73.6% upside for TLRY (target: $10) vs -12.2% for CRON (target: $2).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $10.00 | $2.30 |
| # AnalystsCovering analysts | 20 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.0% |
CRON leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 2 (Valuation Metrics, Total Returns).
TLRY vs CRON: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is TLRY or CRON a better buy right now?
For growth investors, Cronos Group Inc.
(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus 4. 8% for Tilray Brands, Inc. (TLRY). Analysts rate Tilray Brands, Inc. (TLRY) a "Hold" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TLRY or CRON?
Over the past 5 years, Tilray Brands, Inc.
(TLRY) delivered a total return of -59. 3%, compared to -65. 6% for Cronos Group Inc. (CRON). Over 10 years, the gap is even starker: CRON returned +1488% versus TLRY's -74. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TLRY or CRON?
By beta (market sensitivity over 5 years), Cronos Group Inc.
(CRON) is the lower-risk stock at 0. 98β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 107% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 22% for Tilray Brands, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TLRY or CRON?
By revenue growth (latest reported year), Cronos Group Inc.
(CRON) is pulling ahead at 64. 4% versus 4. 8% for Tilray Brands, Inc. (TLRY). On earnings-per-share growth, the picture is similar: Cronos Group Inc. grew EPS -100. 0% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TLRY or CRON?
Cronos Group Inc.
(CRON) is the more profitable company, earning -4. 9% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps -4. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRON leads at -1. 5% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — CRON leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TLRY or CRON more undervalued right now?
Analyst consensus price targets imply the most upside for TLRY: 73.
6% to $10. 00.
07Which pays a better dividend — TLRY or CRON?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is TLRY or CRON better for a retirement portfolio?
For long-horizon retirement investors, Cronos Group Inc.
(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1488% 10Y return). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1488%, TLRY: -74. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TLRY and CRON?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TLRY is a small-cap quality compounder stock; CRON is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.